Patents by Inventor William D. Figg
William D. Figg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10246463Abstract: Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 ? subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.Type: GrantFiled: April 6, 2016Date of Patent: April 2, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kirk R. Gustafson, Martin J. Schnermann, Susanna T. S. Chan, Paresma R. Patel, William D. Figg, James B. McMahon
-
Patent number: 10094836Abstract: The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.Type: GrantFiled: January 8, 2008Date of Patent: October 9, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: William D. Figg, Alex Sparreboom, Akinobu Hamada, Douglas K. Price, Tristan M. Sissung
-
Publication number: 20180093995Abstract: Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 a subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.Type: ApplicationFiled: April 6, 2016Publication date: April 5, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Kirk R. Gustafson, Martin J. Schnermann, Susanna T. S. Chan, Paresma R. Patel, William D. Figg, James B. McMahon
-
Patent number: 9676788Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).Type: GrantFiled: February 5, 2015Date of Patent: June 13, 2017Assignees: The United States of America, as represented by the Secretary of Health and Human Services, University of HawaiiInventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
-
Publication number: 20160347764Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).Type: ApplicationFiled: February 5, 2015Publication date: December 1, 2016Applicants: The United State of America, as represented by the Secretary, Department of Health and Human Service, University of HawaiiInventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
-
Publication number: 20140309436Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: ApplicationFiled: June 25, 2014Publication date: October 16, 2014Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 8853253Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: GrantFiled: October 10, 2012Date of Patent: October 7, 2014Assignee: P2D, Inc.Inventors: Nigel H. Greig, Harold Holloway, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 8835115Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.Type: GrantFiled: July 13, 2007Date of Patent: September 16, 2014Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Universitätsklinikum FreiburgInventors: William D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke
-
Patent number: 8716315Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.Type: GrantFiled: July 19, 2007Date of Patent: May 6, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: William D. Figg, Kurt Eger, Uwe Teubert, Michael Weiss, Michael Guetschow, Thomas Hecker, Sunna Hauschildt
-
Patent number: 8546430Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: GrantFiled: June 3, 2011Date of Patent: October 1, 2013Assignee: P2D, Inc.Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Publication number: 20130035363Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: ApplicationFiled: October 10, 2012Publication date: February 7, 2013Applicants: The United States of America as represented by the Department of Health & Human Services, P2D INC.Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 8143252Abstract: Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 10, 2008Date of Patent: March 27, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: William D. Figg, Erin Gardner, Michael Gutschow, Agnieszka Ambrozak
-
Publication number: 20110245210Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: ApplicationFiled: June 3, 2011Publication date: October 6, 2011Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Patent number: 7973057Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.Type: GrantFiled: September 17, 2004Date of Patent: July 5, 2011Assignees: The United States of America as represented by the Department of Health and Human Services, P2D Inc.Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
-
Publication number: 20100317726Abstract: The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.Type: ApplicationFiled: January 8, 2008Publication date: December 16, 2010Applicant: Government of the United States of America, as rep resented by the Secretary Dept. of Health and HumInventors: William D. Figg, Alex Sparreboom, Akinobu Hamada, Douglas K. Price, Tristan M. Sissung
-
Publication number: 20100280084Abstract: The invention relates to pharmacology, pharmacokinetics and toxicology, and more specifically to methods of identifying and predicting inter-patient differences in response to drugs in order to achieve superior efficacy and safety in selected patient populations. It further related to the genetic basis of inter-patient variation in response to therapy, including drug therapy, and to methods for determining and exploiting such differences to improve medical outcomes.Type: ApplicationFiled: September 8, 2006Publication date: November 4, 2010Applicant: Government of the US, as represented by the Secret ary, Department of Health and Human ServicesInventors: William D. Figg, Alex Sparreboom, Tristan M. Sissung, Douglas K. Price
-
Publication number: 20100247481Abstract: The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.Type: ApplicationFiled: July 13, 2007Publication date: September 30, 2010Inventors: William D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke
-
Publication number: 20090325156Abstract: The invention provides methods and materials for screening for polymorphic variants in ABCB1 and diagnosing altered susceptibilities for drug-induced heart rhythm irregularities based on the same. These methods allow better treatment regimens for using drugs that bind a protein encoded by the ABCB1 and/or induce heart rhythm irregularities such as the anti-cancer drug FK228.Type: ApplicationFiled: November 9, 2006Publication date: December 31, 2009Applicant: Government of the United States of America, as Represented by Secretary, Dept. of Human ServicesInventors: William D. Figg, Alexander Sparreboom, Tristan Sissung, Richard L. Piekarz, Susan E. Bates
-
Publication number: 20090186913Abstract: Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 10, 2008Publication date: July 23, 2009Inventors: William D. Figg, Erin Gardner, Michael Gutschow, Agnieszka Ambrozak
-
Patent number: 7320991Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.Type: GrantFiled: February 26, 2002Date of Patent: January 22, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: William D. Figg, Kurt Eger, Uwe Teubert, Michael Weiss, Michael Guetschow, Thomas Hecker, Sunna Hauschildt